Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. Show more

Location: 2749 East Parleys Way, Salt Lake City, UT, 84109, United States | Website: https://www.sera.com | Industry: Medical Devices | Sector: Healthcare


Market Cap

118.1M

52 Wk Range

$1.37 - $9.13

Previous Close

$3.06

Open

$2.98

Volume

17,752

Day Range

$2.96 - $3.21

Enterprise Value

77.24M

Cash

40.16M

Avg Qtr Burn

-6.57M

Insider Ownership

10.89%

Institutional Own.

60.14%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date